| abstract |
A useful pharmaceutical composition for the treatment of nasal cramping, itching and runny nose, nasal congestion, red eyes, tearing, itchy ears or palate, shortness of breath, inflammation of the bronchial mucosa, forced expiratory volume in a second. (FEV1) reduced, cough, rash, itchy skin, persistent headaches and aches and pains associated with allergic rhinitis, permanent allergic rhinitis, common colds, otitis, sinusitis, allergy, asthma, allergic asthma and / or inflammation, in a mammalian orgasm that needs this treatment. The composition comprises: i) an effective amount of at least one leukotriene antagonist selected from g) montelukast, h) 1 - (((R) - (3- (2- (6,7-difluoro-2-quinolinyl)) acid ethenyl) phenyl) -2- (2- (2-hydroxy-2-propyl) phenyl) thio) methylcylpropanoacetic; i) 1 - (((1 (R) -3 (3- (2- (2,3- dichlorothiene [3,2-b] pyridin-5-yl) - (E) -ethenyl) phenyl-2- (2- (1-hydroxy-1-methylethyl) phenyl) propyl) thio) methyl) cyclopropane-acetic; j ) pranlukast; or k) zafirlukast; or l) [2 - [[2- (4-tert-butyl-2-thiazolyl) -5-benzofuranyl] oxymethyl] phenyl] acetic acid; or its pharmaceutically acceptable salt; mixed with ii) an effective amount of at least one antihistamine which is desacarboethoxyloratidine, cetirizine, fexofenadine, ebastine, astemizole, norastemizole, epinastine, efletirizine or its pharmaceutically acceptable salt. |